Gomez-Arguelles J M, Dorado R, Sepulveda J M, Herrera A, Arrojo F Gilo, Aragón E, Huete C Ruiz, Terrón C, Anciones B
Department of Neurology, Sanatorio De Nuestra Señora del Rosario, Principe De Vergara 53, 28006 Madrid, Spain.
J Clin Neurosci. 2008 May;15(5):516-9. doi: 10.1016/j.jocn.2007.04.010. Epub 2008 Apr 2.
The objective of this prospective open-label study was to evaluate the efficacy and tolerability of oxcarbazepine in trigeminal neuralgia (TN) unresponsive to treatment with the standard antiepileptic drug, carbamazepine. Thirty-five patients with idiopathic TN, who underwent treatment with oxcarbazepine monotherapy for at least 12 weeks, were studied. Pain was assessed using mean pain frequency, responder rate, pain-free patients and clinical global impression. The mean maintenance dose was 773.7 mg/day. There was a significant decrease in the mean of the main scores following 12 weeks of treatment (p<0.05) compared with baseline. Oxcarbazepine was effective from the first month of treatment. There was a significant reduction in pain frequency, leading to improvements in patient satisfaction. In general, oxcarbazepine was well tolerated. Oxcarbazepine appears to be an important alternative therapeutic approach for patients affected by TN. This study adds to the existing literature arriving at the same findings.
这项前瞻性开放标签研究的目的是评估奥卡西平对标准抗癫痫药物卡马西平治疗无效的三叉神经痛（TN）的疗效和耐受性。对35例接受奥卡西平单药治疗至少12周的特发性TN患者进行了研究。使用平均疼痛频率、缓解率、无疼痛患者和临床总体印象来评估疼痛。平均维持剂量为773.7毫克/天。与基线相比，治疗12周后主要评分的平均值显著降低（p<0.05）。奥卡西平从治疗的第一个月起就有效。疼痛频率显著降低，患者满意度得到改善。总体而言，奥卡西平耐受性良好。奥卡西平似乎是TN患者的一种重要替代治疗方法。这项研究补充了现有文献，得出了相同的结果。
